Predictive Ability of C-Reactive Protein in Detecting Short-Term Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Retrospective Cross-Sectional Study.


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 01 08 2019
pubmed: 12 6 2020
medline: 15 5 2021
entrez: 12 6 2020
Statut: ppublish

Résumé

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment for peritoneal carcinomatosis. The aim of this study was to determine the predictive value of postoperative inflammatory biomarkers in assessing complications after CRS and HIPEC. A prospective database of 181 patients, who underwent CRS-HIPEC between March 2014 through April 2018 in the Erasmus MC, was retrospectively analyzed. Postoperative complications were defined according to the serious adverse event (SAE) grading system. Levels of C-reactive protein (CRP) and white blood cell (WBC) count were compared between patients with SAE grade < 3 and SAE grade ≥ 3. The area under the receiver operating characteristic curve (AUC) was calculated for CRP and WBC against SAE ≥ 3 and various intra-abdominal complications. SAE ≥ 3 postoperative complications occurred in 50 patients. From the second until the fifth postoperative day (POD), CRP levels were significantly higher (p = 0.023, p < 0.001, p = 0.002, and p = 0.002, respectively) in these patients. CRP concentrations above 166 mg/L on POD3 (AUC 0.75) and 116 mg/L on POD4 (AUC 0.70) were associated with the highest risk of an SAE ≥ 3. Postoperative WBC levels were not significantly different between patients with SAE < 3 and SAE ≥ 3 complications. Data from our hospital suggest that CRP levels that continue to rise after POD2 or that are ≥ 166 mg/L at POD3 or ≥ 116 mg/L at POD4, indicate a considerable risk for developing high-grade SAEs. The cut-off values we found can potentially be used as a threshold for additional diagnostic interventions, after they have been validated in external data.

Sections du résumé

BACKGROUND BACKGROUND
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment for peritoneal carcinomatosis.
OBJECTIVE OBJECTIVE
The aim of this study was to determine the predictive value of postoperative inflammatory biomarkers in assessing complications after CRS and HIPEC.
METHODS METHODS
A prospective database of 181 patients, who underwent CRS-HIPEC between March 2014 through April 2018 in the Erasmus MC, was retrospectively analyzed. Postoperative complications were defined according to the serious adverse event (SAE) grading system. Levels of C-reactive protein (CRP) and white blood cell (WBC) count were compared between patients with SAE grade < 3 and SAE grade ≥ 3. The area under the receiver operating characteristic curve (AUC) was calculated for CRP and WBC against SAE ≥ 3 and various intra-abdominal complications.
RESULTS RESULTS
SAE ≥ 3 postoperative complications occurred in 50 patients. From the second until the fifth postoperative day (POD), CRP levels were significantly higher (p = 0.023, p < 0.001, p = 0.002, and p = 0.002, respectively) in these patients. CRP concentrations above 166 mg/L on POD3 (AUC 0.75) and 116 mg/L on POD4 (AUC 0.70) were associated with the highest risk of an SAE ≥ 3. Postoperative WBC levels were not significantly different between patients with SAE < 3 and SAE ≥ 3 complications.
CONCLUSION CONCLUSIONS
Data from our hospital suggest that CRP levels that continue to rise after POD2 or that are ≥ 166 mg/L at POD3 or ≥ 116 mg/L at POD4, indicate a considerable risk for developing high-grade SAEs. The cut-off values we found can potentially be used as a threshold for additional diagnostic interventions, after they have been validated in external data.

Identifiants

pubmed: 32524458
doi: 10.1245/s10434-020-08619-y
pii: 10.1245/s10434-020-08619-y
pmc: PMC7752888
doi:

Substances chimiques

C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

233-243

Références

World J Gastrointest Pharmacol Ther. 2016 Aug 6;7(3):434-9
pubmed: 27602245
Cancer. 2010 Dec 15;116(24):5608-18
pubmed: 20737573
J Clin Oncol. 2012 Jul 10;30(20):2449-56
pubmed: 22614976
Crit Care. 2010;14(1):R15
pubmed: 20144219
World J Gastroenterol. 2016 Aug 28;22(32):7226-35
pubmed: 27621570
J Am Coll Surg. 2014 Apr;218(4):573-85
pubmed: 24491244
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S898-904
pubmed: 26014156
Gastroenterol Res Pract. 2019 May 2;2019:2824073
pubmed: 31191642
Int J Colorectal Dis. 2015 Jul;30(7):861-73
pubmed: 25935447
ANZ J Surg. 2006 Jul;76(7):579-85
pubmed: 16813622
Ann Surg Oncol. 2013 Dec;20(13):4224-30
pubmed: 23897008
Ann Surg Oncol. 2014 May;21(5):1494-500
pubmed: 23990289
J Surg Oncol. 2007 Aug 1;96(2):102-12
pubmed: 17221852
Patient Saf Surg. 2010 Mar 25;4(1):5
pubmed: 20338045
Eur J Surg Oncol. 2010 Jul;36(7):599-603
pubmed: 20605396
Ann Surg Oncol. 1999 Dec;6(8):790-6
pubmed: 10622509
Eur J Cardiothorac Surg. 2006 Jul;30(1):64-71
pubmed: 16730447
JAMA Surg. 2014 Feb;149(2):170-5
pubmed: 24352601
Colorectal Dis. 2011 May;13(5):583-7
pubmed: 20163424
Ann Surg Oncol. 2003 Oct;10(8):863-9
pubmed: 14527903
Gastroenterol Res Pract. 2012;2012:836425
pubmed: 22778724
Surg Today. 2010 Sep;40(9):793-808
pubmed: 20740341
Int J Colorectal Dis. 2011 Nov;26(11):1405-13
pubmed: 21701807
Cancer Chemother Pharmacol. 2018 Apr;81(4):697-704
pubmed: 29429054
J Gastrointest Surg. 2015 Apr;19(4):613-24
pubmed: 25663633
Oncotarget. 2017 Apr 27;8(33):55657-55683
pubmed: 28903452
Ann Surg Oncol. 2008 Sep;15(9):2426-32
pubmed: 18521686
Ann Surg Oncol. 2015 Apr;22(4):1332-40
pubmed: 25234021
Ann Med. 2000 May;32(4):274-8
pubmed: 10852144
Cancer Treat Res. 1996;82:359-74
pubmed: 8849962
World J Surg. 2010 Apr;34(4):808-14
pubmed: 20049435
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007

Auteurs

Job P van Kooten (JP)

Department of Surgical Oncology, Erasmus MC Cancer Centre, Rotterdam, The Netherlands.

Arvind Oemrawsingh (A)

Department of Surgical Oncology, Erasmus MC Cancer Centre, Rotterdam, The Netherlands.

Nadine L de Boer (NL)

Department of Surgical Oncology, Erasmus MC Cancer Centre, Rotterdam, The Netherlands.

Cornelis Verhoef (C)

Department of Surgical Oncology, Erasmus MC Cancer Centre, Rotterdam, The Netherlands.

Jacobus W A Burger (JWA)

Department of Surgical Oncology, Erasmus MC Cancer Centre, Rotterdam, The Netherlands.
Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands.

Eva V E Madsen (EVE)

Department of Surgical Oncology, Erasmus MC Cancer Centre, Rotterdam, The Netherlands.

Alexandra R M Brandt-Kerkhof (ARM)

Department of Surgical Oncology, Erasmus MC Cancer Centre, Rotterdam, The Netherlands. a.brandt-kerkhof@erasmusmc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH